BOARD OF DIRECTORS

  • Christian Henry

    President & Chief Executive Officer

    Christian Henry has more than two decades of experience with growing companies in the life sciences industry. From 2005 through January 2017, Mr. Henry was an executive at Illumina, Inc., where he served in a number of different roles including Chief Financial Officer, Chief Commercial Officer and General Manager of the Life Sciences Business. Prior to Illumina, Mr. Henry was Chief Financial Officer for Tickets.com, a publicly traded online ticket provider, which was acquired by Major League Baseball Advanced Media, LP. Mr. Henry also served as Vice President of Finance and Corporate Controller for Affymetrix, Inc., and held a similar position at Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.). Mr. Henry earned a BA in biochemistry and cell biology from the University of California, San Diego and an MBA from the University of California, Irvine.

    Independent Director
  • Michael Hunkapiller, PH.D.

    Senior Fellow

    Michael Hunkapiller recently transitioned to Senior Fellow after serving as the President & CEO of Pacific Biosciences from 2012 - 2020. He has served on the Board since 2005. Dr. Hunkapiller spent over 30 years of his career helping build Applied Biosystems (“ABI,” now part of Thermo Fisher Scientific Inc.) into a market leader in the life sciences industry. From 1995 to 2004, he served as ABI’s President and General Manager. In 2004, he joined Alloy Ventures as a General Partner, and in 2005 led Alloy’s investment in PacBio.

    During his term at ABI, Dr. Hunkapiller developed the R&D strategies and alliances that elevated ABI to be the foremost supplier of molecular-biology reagents and instrumentation in academic and industrial laboratories. He was also a founder of ABI’s sister company, Celera Genomics, and Senior Vice President of Applera Corporation (Celera’s parent company).

    Prior to joining ABI, Dr. Hunkapiller was a senior research fellow in the Division of Biology at the California Institute of Technology. He received a B.S. in Chemistry from Oklahoma Baptist University and a Ph.D. in Chemical Biology from the Division of Chemistry and Chemical Engineering at Caltech. He has authored more than 100 scientific publications, is an inventor on more than two-dozen patents, and has served on the editorial boards of several scientific journals. He has received several awards for his contributions to life science research.

    • David Botstein

      Chief Scientific Officer, Calico Life Sciences, LLC

      David Botstein, Ph.D., is Chief Scientific Officer of Calico Life Sciences, LLC. He was the Anthony B. Evnin Professor of Genomics, Emeritus at Princeton University, where he also served as Director of the Lewis-Sigler Institute for Integrative. From 1990-2003 he was Chairman of the Department of Genetics at Stanford University. From 1987-1990 he was Vice President for Science at Genentech and remained a member of its Science Resource Board until 2014. He is a member of the National Academy of Sciences and the Institute of Medicine, and has received numerous awards for his achievements in science. Dr. Botstein has made fundamental contributions to modern genetics, including the discovery of many yeast and bacterial genes and the establishment of key techniques that are commonly used today. In 1980, Botstein and three colleagues proposed a method for mapping genes that laid the groundwork for the Human Genome Project. Dr. Botstein holds a Ph.D. in Human Genetics from the University of Michigan and an A.B. in Biochemical Sciences from Harvard.

      Independent Director
    • Bill Ericson

      Founding Partner, Wildcat Venture Partners

      William Ericson has been a member of our Board of Directors since 2004. Mr. Ericson is a Founding Partner at Wildcat Venture Partners where he focuses on investments in Digital Health. He is also a General Partner at Mohr Davidow Ventures (MDV) where he has led the firm’s focus on personalized medicine investing since 2003.

      Mr. Ericson holds a B.S.F.S. from Georgetown University School of Foreign Service and a J.D. from Northwestern University School of Law. We believe that Mr. Ericson possesses specific attributes that qualify him to serve as a member of our Board of Directors, including his experience with multiple companies in the life sciences industry and his focus on companies with molecular diagnostic platforms that will enable the vision of personalized medicine.

      Independent Director
    • Randy Livingston

      Vice President for Business Affairs and Chief Financial Officer, Stanford University

      Randy Livingston has been  Vice President for Business Affairs and Chief Financial Officer of Stanford University since 2001.  Before joining Stanford, Mr. Livingston served as the Executive Vice President, Chief Financial Officer and a Director of OpenTV Corp. from 1999 to 2001.  Prior to joining OpenTV, Mr. Livingston served as a consultant and part-time Chief Financial Officer for Silicon Valley technology companies with such diverse specialties as Genomics, Internet Commerce, Medical Devices, Chemical Synthesis and Enterprise Software.  Previously, he was director of corporate development at Apple Computer and Chief Financial Officer for Taligent, Inc., a 400-employee Apple-IBM-Hewlett-Packard joint venture system softward comany.  Mr. Livingston currently serves as a director of eHealth, Inc.

      Mr. Livingston holds a B.S. in Mechanical Engineering and an M.B.A. from Stanford University.

      Independent Director
    • John F. Milligan, Ph.D.

      Chairman of the Board

      John F. Milligan, PhD has served as the Chair of our board of directors since September 2020. Dr. Milligan had a 29-year career with Gilead, retiring as President and Chief Executive Officer in December 2018. During his tenure at Gilead, he led teams that developed, manufactured and commercialized more than 25 new therapies for significant unmet needs, including the first single tablet regimen for HIV treatment and the first 12 week, all oral cure for HCV. John led multiple transformative acquisitions including Triangle Pharmaceuticals in 2003, Myogen in 2006, CV Therapeutics in 2009, Pharmassett in 2012 and Kite in 2017.

      Before taking the CEO role, as CFO, John built a robust international organization that allowed the company to grow from $190 million in revenue to over $4.2 billion in just six years. He helped the company become a global organization with direct operations in 44 countries that was able to deliver its medicines to more than 10 million patients every day. John joined Gilead when it was a private company with 32 employees, and upon retirement, 29 years later, Gilead had over 11,000 employees, sales of over $21 billion and a market cap of $85 billion. In addition to his role as Chair of PacBio, John is currently the Executive Chair of 4D Molecular Therapeutics, a privately held gene-therapy company and also serves as the Chair of the Board of Trustees of Ohio Wesleyan University. John received a B.A. in chemistry from Ohio Wesleyan University, a Ph.D. in biochemistry from the University of Illinois at Urbana-Champaign and was an American Cancer Society post-doctoral fellow at U.C.S.F.

      Independent Director
      Chairman of the Board
    • Marshall L. Mohr

      Senior Vice President & Chief Financial Officer, Intuitive Surgical Inc.

      Since March 2006, Marshall L. Mohr has been the Senior Vice President and Chief Financial Officer of Intuitive Surgical, Inc.,  a provider of surgical robotics.  Prior to joining Intuitive Surgical, Mr. Mohr served as Vice President and Chief Financial Officer of Adaptec, Inc. Before 2003, Mr. Mohr was an Audit Partner with PricewaterhouseCoopers LLP where he was most recently the Managing Partner of the firm's West Region Technology Industry Group and led its Silicon Valley accounting and auditing advisory practice.  Since 2005, Mr. Mohr has been a member of the Board of Directors and Chairman of the Audit Committee of Plantronics, Inc., a provider of lightweight communications headsets and telephone headset systems, and also served as a member of the Board of Directors and Chairman of the Audit Committee of Atheros Communications, Inc., a developer of semiconductor system solutions for wireless communications products, from November 2003 to May 2011 when Atheros was sold to Qualcomm, Inc. 

      Mr. Mohr holds a Bachelor of Business Administration in Accounting and Finance from Western Michigan University.

      Independent Director
    • Kathy Ordoñez

      Kathy Ordoñez brings more than 30 years of experience in the life sciences and diagnostics industries. From January 2012 until June 2013, Ms. Ordoñez was a Senior Vice President at Quest Diagnostics Inc., a leading provider of diagnostic information services, where she was initially responsible for leading the company’s R&D effort and later provided oversight to multiple businesses commercializing diagnostic products and testing services. She joined Quest Diagnostics as part of its acquisition of Celera Corporation, a leading provider of genetic testing products for HIV resistance, Cystic Fibrosis and high complexity tissue transplantation, in 2011. From April 2002 until May 2011, Ms. Ordoñez was the Chief Executive Officer at Celera and she founded Celera Diagnostics in December 2000. From 1985 until 2000, Ms. Ordoñez held several senior positions at Hoffmann- La Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the Polymerase Chain Reaction (PCR) technology to the research, diagnostic and forensic fields. Ms. Ordoñez also served as Director, non-Executive Chairman, and Chief Executive Officer of RainDance Technologies, Inc., which was sold to Bio-Rad Laboratories, Inc. in February 2017. In mid-2019, Ms. Ordoñez joined the Quidel Corporation Board of Directors.

       

    • Lucy Shapiro

      Developmental Biology Professor, Stanford University School of Medicine

      Dr. Shapiro currently serves as the Virginia and D.K. Ludwig Professor of Cancer Research and the Director of the Beckman Center for Molecular and Genetic Medicine at Stanford University's School of Medicine, where she has been as a faculty member since 1989. Dr. Shapiro is a co-founder and director of Anacor Pharmaceuticals, Inc., which was acquired by Pfizer in 2016.  In 2016, she founded a second anti-infectives company, Boragen, LLC.  In 1989, Dr. Shapiro founded Stanford University's Department of Developmental Biology, and served as its Chairman from 1989 to 1997. Prior to that, Dr. Shapiro served as Chair of the Department of Microbiology and Immunology in the College of Physicians and Surgeons of Columbia University. She received a B.A. from Brooklyn College and a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine.

      Dr. Shapiro has received numerous awards including the National Medal of Science.  She has been and elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences and the National Academy of Medicine for her work in the fields of molecular biology and microbiology. Dr. Shapiro previously served as a non-executive director of GlaxoSmithKline plc from 2001 to 2006.  Dr. Shapiro was also a Director of Gen-Probe, Inc. from 2008 to 2012. 

      Independent Director

    STOCK QUOTE

    Data Provided by Refinitiv. Minimum 15 minutes delayed.

    Investor
    Contact

    Pacific Biosciences

    1305 O’Brien Drive

    Menlo Park, CA  94025

    ir@pacb.com